Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:36 PM ET 8-K
Financial Results Air T Inc AIRT

Air T Financial Results

Air T, Inc. reported financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 129% to $146.9 million, primarily driven by the acquisition of Regional Express Holdings (Rex). The company reported a net loss of $7.48 per share, impacted by operational challenges at Rex including unscheduled engine removals and high fuel costs.

Term
Q2 2027

“While focused in one sector and with some interdependencies, Air T can be viewed as a set of businesses that operate independently of one another. The quarter just passed is an example of widely variable operational dynamics across our businesses.”

Nick Swenson, Company Chairman and CEO

“Rex financial performance was notably challenged in the quarter due to a combination of unscheduled engine removals, delays at engine overhaul shops and a doubling of fuel costs compared to pre-war levels.”

Nick Swenson, Company Chairman and CEO
4:35 PM ET 8-K
Financial Results Calidi Biotherapeutics, Inc. CLDI

Calidi Biotherapeutics Financial Results

Calidi Biotherapeutics reported a net loss of $3.6 million for the third quarter of 2026, a significant improvement from the $10.8 million loss in the prior year period. The company highlighted preclinical progress for its CLD-401 program and implemented a restructuring plan on November 6, 2026, to reduce headcount and save $3 million annually. During the quarter, the company also raised $1.2 million through an at-the-market offering to extend its cash runway.

Term
Q3 2026

“Throughout the third quarter, Calidi continued to advance its RedTail platform for systemic and local delivery and redefine the potential of oncolytic viruses and genetic medicine. In particular, CLD-401 demonstrated remarkable anti-tumor activity with systemic administration in syngeneic tumor models and continues to progress towards the clinic.”

Eric Poma, Ph.D., Calidi Biotherapeutics CEO
4:35 PM ET 10-Q
Financial Results WTI Fund X, Inc.

WTI Fund X Q3 2026 Results: Net Loss of $5.18M

WTI Fund X, Inc. reported a net increase in net assets resulting from operations of $26.2 million for the nine months ended September 30, 2026, down slightly from $27.6 million in the prior year period. The company significantly reduced its debt facility borrowings from $232.5 million at year-end 2025 to $95.0 million, while net assets increased to $209.2 million.

Key figure
Net loss $5.18M
4:35 PM ET 10-Q
Financial Results Adm Endeavors, Inc. ADMQ

Adm Endeavors Q3 2026 Results: Net Income $197K, Down 8.7% YoY

ADM Endeavors, Inc. reported total revenue of $4.58 million for the nine months ended September 30, 2026, a slight increase from $4.31 million in the prior year period. The company achieved a net income of $127,075 for the first nine months of 2026, down from $250,321 in 2025, primarily due to significantly higher interest expenses and the absence of a large gain on an insurance claim seen in the previous year.

Key figure
Net income $197K · -8.7% YoY
4:34 PM ET 10-Q
Financial Results Forbright, Inc. FRBT

Forbright Q3 2026 Results: Net Income $20.6M, Down 35.7% YoY

Forbright, Inc. filed its 10-Q for the period ending September 30, 2026, reporting 33,601,078 shares of Class A common stock outstanding. The filing highlights a pending branch sale agreement and the adoption of the 2026 Omnibus Incentive Plan, while emphasizing risks related to AI implementation and credit quality.

Key figure
Net income $20.6M · -35.7% YoY
4:34 PM ET 10-Q
Financial Results Churchill Capital Corp XI AGLT

Agility Robotics Q3 2026 Results: Turns Profitable, Net Income $109M

Churchill Capital Corp XI (CCXI) completed its business combination with Legacy Agility on November 2, 2026, subsequently changing its name to Agility Robotics, Inc. The filing covers the period ended September 30, 2026, prior to the merger's consummation, and reflects a pre-money equity value for Legacy Agility of $2.5 billion.

Key figure
Net income $109M
4:34 PM ET 10-Q
Financial Results Nexpoint Diversified Real Estate Trust NXDT

Nexpoint Diversified Real Estate Trust Q3 2026 Results: Net Loss of $55.5M, Loss Widens

NexPoint Diversified Real Estate Trust reported total assets of $993.4 million as of September 30, 2026, a decrease from $1.07 billion at year-end 2025. The company experienced a significant increase in its accumulated loss to $458.2 million, while total shareholders' equity declined from $700.1 million to $610.6 million during the nine-month period.

Key figure
Net loss $55.5M
4:34 PM ET 10-Q
Financial Results Broadway Financial Corp \De\ BYFC

Broadway Financial Corp \De\ Q3 2026 Results: Turns Profitable, Net Income $1.14M

Broadway Financial Corp reported net income of $1.1 million for the third quarter of 2026, a significant recovery from a $23.9 million loss in the prior year period which was driven by a $25.9 million goodwill impairment. Total assets grew to $1.56 billion as of September 30, 2026, primarily fueled by a $192.4 million increase in deposits and growth in the loan portfolio.

Key figure
Net income $1.14M
4:34 PM ET 10-Q
Financial Results Air T Inc AIRT

Air T Q2 2026 Results: Net Loss of $20M

Air T Inc. reported a significant increase in operating revenues to $262.4 million for the six months ended September 30, 2026, driven by the addition of regional airline and aviation leasing segments. However, the company swung to a net loss of $35.2 million compared to a profit in the prior year, primarily due to higher operating expenses, increased interest costs, and a $3.4 million earnout remeasurement charge.

Key figure
Net loss $20M
4:34 PM ET 10-Q
Financial Results Kpet Ultra Paceline Corp KPET

Kpet Ultra Paceline Q3 2026 Results: Turns Profitable, Net Income $1.95M

KPET Ultra Paceline Corp reported net income of $3.53 million for the nine months ended September 30, 2026, primarily driven by $4.08 million in interest earned on investments held in the Trust Account. As a shell company, its primary assets consist of $233.8 million in the Trust Account, while it maintains a shareholders' deficit of $11.23 million due to the accretion of Class A ordinary shares to redemption value.

Key figure
Net income $1.95M
4:34 PM ET 10-Q
Financial Results Golden Minerals Co AUMN

Golden Minerals Q3 2026 Results: Net Loss of $750K, Loss Narrows

Golden Minerals Company reported a net loss of $0.7 million for the nine months ended September 30, 2026, an improvement from a $3.0 million loss in the prior year period, primarily due to $1.1 million in income from discontinued operations. The company remains in the exploration stage with no mineral reserves, maintaining a cash balance of $1.7 million as of the end of the third quarter.

Key figure
Net loss $750K
4:34 PM ET 10-Q
Financial Results Moleculin Biotech, Inc. MBRX

Moleculin Biotech Q3 2026 Results: Net Loss of $6.49M, Loss Narrows

Moleculin Biotech reported a net loss of $27.0 million for the nine months ended September 30, 2026, compared to a $49.1 million loss in the prior year period. The company ended the quarter with $7.3 million in cash and cash equivalents, supported by $20.3 million in net cash provided by financing activities during the year.

Key figure
Net loss $6.49M
4:33 PM ET 10-Q
Financial Results Silo Pharma, Inc. SILO

Silo Pharma Q3 2026 Results: Net Loss of $359K, Loss Narrows

For the nine months ended September 30, 2026, Silo Pharma reported a net loss of $2.84 million, an improvement from the $3.35 million loss in the prior year period. The company's cash position increased to $6.09 million, bolstered by a $0.70 million gain from the termination of a sublicense agreement and financing activities.

Key figure
Net loss $359K
4:33 PM ET 10-Q
Financial Results RMG ML Sports Holdings SHOT

RMG ML Sports Holdings Q3 2026 Results: Net Income $1.91M

RMG ML Sports Holdings reported a net loss of $4.30 million for the nine months ended September 30, 2026, primarily driven by $6.79 million in general and administrative expenses. As a shell company, its assets are largely comprised of $218.92 million held in a Trust Account following its initial public offering in mid-2026.

Key figure
Net income $1.91M
4:33 PM ET 10-Q
Financial Results Graf Global Corp. TONT

Graf Global Q3 2026 Results: Net Loss of $5.25K

For the nine months ended September 30, 2026, Graf Global Corp. reported net income of $1,588,180, driven by $5,076,172 in interest earned on trust account funds. The company experienced significant redemptions during the period, with $158,489,876 withdrawn from the Trust Account to redeem Class A ordinary shares.

Key figure
Net loss $5.25K
4:33 PM ET 10-Q
Financial Results Cirtran Corp CIRX

Cirtran Q3 2026 Results: Net Loss of $285K, Loss Narrows

CirTran Corporation reported a significant turnaround for the nine months ended September 30, 2026, with net income of $1,827,615 compared to a net loss of $1,138,064 in the prior year, primarily driven by income from discontinued operations. Net sales increased substantially to $2,996,530 from $1,077,743, although the company continues to carry a significant stockholders' deficit of over $23 million.

Key figure
Net loss $285K
4:33 PM ET 10-Q
Financial Results Rmx Industries, Inc. RMXI

Rmx Industries Q3 2026 Results: Net Loss of $2.34M, Loss Narrows

RMX Industries, Inc. reported a net loss of $19.4 million for the nine months ended September 30, 2026, compared to a $15.0 million loss in the prior year period, driven largely by $10.4 million in losses on warrant conversions. Revenue significantly declined to $3,722 from $311,344 year-over-year as the company pivoted its focus toward physical-edge intelligence and VAST technology.

Key figure
Net loss $2.34M
4:33 PM ET 10-Q
Financial Results Fabric.AI, Inc. FABC

Fabric.AI Q3 2026 Results: Net Loss of $4.91M, Loss Widens

Fabric.AI, Inc. reported a net loss of $19.8 million for the nine months ended September 30, 2026, compared to a $16.1 million loss in the prior year period. The company significantly increased its research and development spending to $10.2 million and ended the quarter with $39.2 million in total assets, largely driven by new issuances of Series J and K convertible preferred stock.

Key figure
Net loss $4.91M
4:33 PM ET 8-K
Financial Results Newton Golf Company, Inc. NWTG

Newton Golf Company Financial Results

Newton Golf Company reported Q3 2026 net sales of $1.4 million, a decline from $2.6 million in the prior year due to marketing agency transitions and strategy changes. Despite lower revenue, the company improved its net loss to $1.2 million compared to $1.6 million in the prior-year quarter, driven by reduced operating expenses. Subsequent to the quarter-end, the company strengthened its balance sheet by raising approximately $3.0 million in net proceeds from equity financings.

Term
Q3 2026
4:33 PM ET 10-Q
Financial Results Central Plains Bancshares, Inc. CPBI

Central Plains Bancshares Q2 2026 Results: Net Income $1.17M, Up 32.2% YoY

Central Plains Bancshares, Inc. reported net income of $2.66 million for the six months ended September 30, 2026, an increase from $1.87 million in the prior year period. The growth was driven by higher net interest income, though the company experienced a significant increase in accumulated other comprehensive loss due to unrealized holding losses on available-for-sale securities.

Key figure
Net income $1.17M · +32.2% YoY
4:33 PM ET 10-Q
Financial Results TurnOnGreen, Inc. TOGI

TurnOnGreen Q3 2026 Results: Net Loss of $456K, Loss Narrows

TurnOnGreen, Inc. reported a net loss of $1.58 million for the nine months ended September 30, 2026, a slight improvement from the $1.70 million loss in the prior year. While revenue grew to $5.15 million, the company faces significant liquidity challenges with a $34.4 million shareholders' deficit and substantial doubt regarding its ability to continue as a going concern.

Key figure
Net loss $456K
4:33 PM ET 8-K
Financial Results Pedevco Corp PED

Pedevco Financial Results

PEDEVCO reported Q3 2026 financial results, highlighted by a 411% year-over-year revenue increase to $35.5 million driven by production growth from its Rockies asset base. Despite higher operating income, the company reported a net loss of $9.2 million primarily due to a $16.6 million loss on derivative contracts. Management updated its full-year capital expenditure guidance to $37-$42 million to reflect accelerated development activity and lease acquisitions.

Term
Q3 2026
4:33 PM ET 10-Q
Financial Results Annovis Bio, Inc. ANVS

Annovis Bio Q3 2026 Results: Net Loss of $9.46M, Loss Widens

Annovis Bio reported a net loss of $41.9 million for the nine months ended September 30, 2026, compared to $19.0 million in the prior year, driven primarily by a significant increase in research and development expenses. The company's cash position decreased to $2.8 million from $19.5 million at the end of 2025, though it raised approximately $30.2 million through equity and warrant issuances during the period.

Key figure
Net loss $9.46M
4:32 PM ET 10-Q
Financial Results Fdctech, Inc. FDCT

Fdctech Q3 2026 Results: Net Loss of $6.32M

For the nine months ended September 30, 2026, FDCTech reported a significant revenue increase to $35.9 million compared to $17.3 million in the prior year, driven largely by its Brokerage (Trading) segment. Net income attributable to shareholders rose to $8.26 million, though the company experienced a net loss of $6.32 million in the third quarter of 2026 due to high costs of sales and operating expenses.

Key figure
Net loss $6.32M
4:32 PM ET 10-Q
Financial Results Dss, Inc. DSS

Dss Q3 2026 Results: Net Loss of $4.65M, Loss Widens

DSS, INC. reported a total revenue of $11.5 million for the nine months ended September 30, 2026, a decrease from $16.6 million in the prior year period. The company experienced a net loss of $16.3 million during this period, driven by higher operating costs and losses on investments, resulting in a total stockholders' equity of $4.3 million.

Key figure
Net loss $4.65M
4:32 PM ET 10-Q
Financial Results Microbot Medical Inc. MBOT

Microbot Medical Q3 2026 Results: Net Loss of $5.84M, Loss Widens

Microbot Medical Inc. reported a net loss of $15.14 million for the nine months ended September 30, 2026, compared to $9.68 million in the prior year, as the company began generating initial revenues of $418,000. Operating expenses increased significantly, particularly in sales and marketing, while cash and marketable securities decreased to approximately $61.8 million.

Key figure
Net loss $5.84M
4:32 PM ET 10-Q
Financial Results Peraso Inc. PRSO ▶ Call

Peraso Q3 2026 Results: Net Loss of $2.66M, Loss Widens

Peraso Inc. reported a significant decline in total net revenue to $0.3 million for the third quarter of 2026, down from $3.2 million in the prior year period, primarily due to lower product sales. The company's net loss widened to $2.7 million for the quarter, and cash reserves decreased to $0.6 million as of September 30, 2026, compared to $2.9 million at the end of 2025.

Key figure
Net loss $2.66M
4:32 PM ET 10-Q
Financial Results General Catalyst Global Resilience Merger Corp. GCGR

General Catalyst Global Resilience Merger Q3 2026 Results: Net Income $3.39M

General Catalyst Global Resilience Merger Corp. is a blank check company that completed its IPO on May 1, 2026, raising $402.5 million. For the period from inception through September 30, 2026, the company reported net income of $5.17 million, primarily driven by $5.89 million in interest earned on cash held in the Trust Account, offset by $0.72 million in operating expenses.

Key figure
Net income $3.39M
4:32 PM ET 8-K
Financial Results Vuzix Corp VUZI

Vuzix Financial Results

Vuzix Corporation reported third quarter 2026 financial results, showing a 38% revenue decline to $0.7 million as the company transitions toward an OEM-focused business model. The company reported a net loss of $8.4 million ($0.10 per share) while highlighting progress in its defense business and the launch of its Causeway optical interconnect platform.

Term
Q3 2026

“During the third quarter, Vuzix continued to advance its transition towards a more OEM-focused business built around advanced waveguide technologies, optical engineering and its U.S.-based manufacturing capabilities.”

Paul Travers, President and CEO of Vuzix
4:32 PM ET 10-Q
Financial Results TRex Bio, Inc. TRXB

TRex Bio Q3 2026 Results: Net Loss of $13.2M, Loss Widens

TRex Bio, Inc. is a clinical-stage biopharmaceutical company that has incurred substantial losses since inception and expects these losses to increase as it develops its autoimmune and inflammatory disease product candidates. As of November 5, 2026, the company had 28,788,654 shares of common stock outstanding and is classified as an emerging growth company.

Key figure
Net loss $13.2M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.